[home]
[thesaurus]
Click Here to return To Results
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
See this aricle in Pubmed
Article Abstract
In relapsing-remitting MS patients, both the currently-approved GA 20mg and 40mg doses were safe and well-tolerated, with no gain in efficacy for the higher dose.
Related Tags
(click to filter results - removes previous filter)
cop 1
efficacy
multiple sclerosis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
safety
tolerance
Click Here to return To Results